Antineoplastic Agents. 606. the Betulastatins

George Pettit, Noeleen Melody, Jean Chapuis

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The medicinal potential of the plant pentacyclic triterpene betulin has generated long-term interest focused on various SAR research avenues. The present approach was based on producing further analogues (chimeras) arising from a studied modification of betulin bonded to the Dov-Val-Dil-Dap unit of the powerful anticancer drug dolastatin 10, which provided betulastatins 1 (7b), 2 (11b), 3 (16b), and 4 (18b). Betulastatin 1, 2, and 4 exhibited modest levels of cancer cell growth inhibition against six cancer cell lines. Betulastatin 3 proved to be the most potent cancer cell growth inhibitor (GI 50 0.01 μg/mL) and seems worthy of further development, as the presumed mixture of anticancer mechanisms of action may prove to be useful.

Original languageEnglish (US)
Pages (from-to)458-464
Number of pages7
JournalJournal of Natural Products
Issue number3
StatePublished - Mar 23 2018

ASJC Scopus subject areas

  • Analytical Chemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine
  • Organic Chemistry


Dive into the research topics of 'Antineoplastic Agents. 606. the Betulastatins'. Together they form a unique fingerprint.

Cite this